Microbiomics: Novel Biomarkers of Colorectal Cancer Diagnosis and Prognosis
A narrative review maps gut microorganisms and metabolites as candidate diagnostic and prognostic biomarkers in colorectal cancer.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The abstract describes mechanisms by which Fusobacterium nucleatum and enterotoxigenic Bacteroides fragilis promote tumorigenesis, while Faecalibacterium prausnitzii and Akkermansia muciniphila exert protective effects via short-chain fatty acids. Metabolically, hydrogen sulfide damages mitochondrial DNA and secondary bile acids stimulate cell proliferation. Clinical data cited associate F. nucleatum with advanced tumor stage.
How it was done
Narrative review of current evidence on gut microbiome and CRC; the available abstract does not specify search criteria, databases, or coverage period.
Risk of bias
Narrative reviews lack quantitative synthesis and are prone to selection bias. The abstract is truncated, preventing full assessment of conclusions and methodological quality.
What this study does NOT prove
It cannot be concluded that any microbial biomarker cited has validated diagnostic accuracy or prognostic value for clinical application.
In clinical practice
No change in clinical practice is warranted based on this review alone. The described biomarker candidates lack consolidated clinical validation for routine diagnostic or prognostic use.
Limitations
Narrative reviews lack quantitative synthesis and are prone to selection bias. The abstract is truncated, preventing full assessment of conclusions and methodological quality.
Technical appendix
Version history
- 1.0 · 2026-08-21 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.